重组促红细胞生成素治疗肾性贫血的观察  

Observation on Effects of Recombinant Human Erythropoietin (r-HuEPO) in Renal Anaemia

作　　者：朱淑兰[1] 翟德佩[1] 赵立全[1] 阎然 李扬 毕军 张弘 

机构地区：[1]天津医学院附属医院肾科,300052

出　　处：《天津医药》1993年第11期659-662,共4页Tianjin Medical Journal

摘　　要：应用重组促红细胞生成素(r-HuEPO)治疗60例慢性肾功能衰竭(CRF)患者的贫血,根据红细胞压积(Hct)水平,将病人分为25U/kg组、50U/kg组、100U/kg组及200U/kg组,共4组。治疗8周后患者的Hct及血红蛋白(Hb)均有升高,依赖输血者不需再输血。血清铁蛋白(FePr)随Hct、Hb的上升而下降,呈负相关趋势。未透析病人的血浆粘度在治疗后明显上升(P<0.01)。血白细胞(WBC)、血小板(Pc)、血钙(Ca)、血磷(P)、血尿素氮(BUN)、肌酐(Cr)、叶酸(FA)及B_(12)等水平治疗前后无明显差别。治疗后症状明显减轻或消失。结果认为r-HuEPO能有效地纠正CRF的贫血,安全可靠、副作用少。治疗中应随时监测铁储备,必要时应及时补充铁剂。The observation was made on the effects of r-HuEPO in 60 patients with chronic renal failure. Significant improvements of Hct and Hb were found after 8 week's treatment with r-HuEPO. The patients did not rely on blood transfusion any more. At the same time, there was a negative correlation between Hct and Hb, and serum ferritin. It showed that Hct and Hb were elevated while ferritin was declined. The symptoms were relieved or even vanished. A conclusion was drawn that the anaemia in patients with chronic renal failure could be effectively corrected by r-HuEPO which appeared to be safe and have less side effects. It should be emphasized that the reservation in the patients, who are currently under the treatment with the medicine, should be monitored. The iron supplementation should be made if necessary.

关 键 词：肾功能衰竭 红细胞生成素 贫血 

分 类 号：R692.506[医药卫生—泌尿科学]